Scholar Rock Holding Corporation
SRRKNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for SRRK. That does not mean none is planned.
Get an email about SRRK's next catalysts
Track Scholar Rock Holding (SRRK) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 1 past
SRRK Earnings Report
EPS Est: $-0.87 | FQ end Sep/2026 | Call: bmo
Market Overview
Stock performance and key metrics
Apitegromab
Spinal Muscular Atrophy
SRK-015
Spinal Muscular Atrophy
Nusinersen
Spinal Muscular Atrophy
Risdiplam
Spinal Muscular Atrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Apitegromab | Phase 3 | Spinal Muscular Atrophy | - | - |
SRK-015 | Phase 2 | Spinal Muscular Atrophy | - | - |
Nusinersen | Phase 2 | Spinal Muscular Atrophy | - | - |
Risdiplam | Phase 2 | Spinal Muscular Atrophy | - | - |
Frequently asked questions
What is in Scholar Rock Holding Corporation's drug pipeline?→
CatalystAlert tracks 4 drug candidates in Scholar Rock Holding Corporation's (SRRK) pipeline across Phase 3, Phase 2. Its lead program is Apitegromab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Scholar Rock Holding Corporation's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Scholar Rock Holding Corporation (SRRK) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track SRRK biotech catalysts?→
Add SRRK to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scholar Rock Holding Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.